Citigroup
ZBIO

Citigroup’s Zenas BioPharma ZBIO Stock Holding History

Citigroup’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
49,521
+39,633
+401% +$788K ﹤0.01% 3286
2026
Q1 		$193K Buy
9,888
+7,537
+321% +$169K ﹤0.01% 4019
2025
Q4 		$85.4K Buy
2,351
+2,163
+1,151% +$71.1K ﹤0.01% 4385
2025
Q3 		$4.17K Sell
188
-5,263
-97% -$85.7K ﹤0.01% 5278
2025
Q2 		$52.8K Sell
5,451
-5,359
-50% -$52.2K ﹤0.01% 4730
2025
Q1 		$85.4K Sell
10,810
-1,294
-11% -$10.1K ﹤0.01% 4683
2024
Q4 		$99.1K Buy
+12,104
New +$189K ﹤0.01% 4845

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Citigroup's ZBIO Position: Q2 2026 in Review

Citigroup increased its Zenas BioPharma (ZBIO) stake by 401% in Q2 2026, buying an estimated $788K and bringing the position to 49,521 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #3286.

Citigroup first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Citigroup held 49,521 shares of Zenas BioPharma worth $1.26M as of Q2 2026.
  • Citigroup bought 39,633 Zenas BioPharma shares in Q2 2026, an estimated $788K.
  • Zenas BioPharma made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3286 holding.
  • Citigroup first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.